文献速递基础与转化研究临床试验与 GCP新药、器械与细胞基因治疗研发

慢病毒β-珠蛋白基因治疗输血依赖型β-地中海贫血

Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia.
PubMed 文献 · N Engl J Med · 2018-01-01

两项1-2期研究纳入22例12至35岁输血依赖型β-地中海贫血患者,回输经LentiGlobin BB305载体转导的自体CD34+细胞,并采用白消安清髓预处理。中位随访26个月时,13例非β0/β0基因型患者中12例已停止红细胞输注;9例β0/β0或携带两份IVS1-110突变患者的年化输血量中位下降73%,其中3例停止输血。

要点

  • 非β0/β0基因型患者中12/13例摆脱红细胞输注
  • β0/β0或双拷贝IVS1-110突变者年输血量中位下降73%
  • 不良事件与自体干细胞移植常见事件相似,未见载体整合相关克隆优势

核心结论

  • 自体CD34+细胞经BB305载体转导的基因治疗可减少或消除22例重型β-地中海贫血患者的长期红细胞输注需求,且未发生与药品相关的严重不良事件。

研究设计与样本

  • 两项1-2期研究,从22例12至35岁输血依赖型β-地中海贫血患者采集动员后的自体CD34+细胞,体外经LentiGlobin BB305载体转导,清髓性白消安预处理后回输。
  • 随访监测不良事件、载体整合及复制competent慢病毒,疗效评估总血红蛋白、HbAT87Q水平、输血需求与平均载体拷贝数。

主要发现

  • 回输后中位26个月(范围15至42)时,13例非β0/β0基因型患者中除1例外均停止红细胞输注。
  • 非β0/β0患者HbAT87Q水平为3.4至10.0 g每分升,总血红蛋白为8.2至13.7 g每分升。
  • 9例β0/β0基因型或携带两份IVS1-110突变患者年化输血量中位下降73%,其中3例停止红细胞输注。
  • 治疗相关不良事件与自体干细胞移植常见事件相似,未观察到载体整合相关克隆优势。

关键数值与推荐

  • 非β0/β0基因型13例中12例停止红细胞输注,HbAT87Q 3.4至10.0 g每分升,总血红蛋白8.2至13.7 g每分升。
  • β0/β0或双拷贝IVS1-110突变9例年化输血量中位下降73%,3例停止输血。

临床怎么用

  • 对输血依赖型β-地中海贫血,尤其是非β0/β0基因型患者,该基因治疗有望减少或免除长期红细胞输注,需评估清髓预处理风险与长期安全性。

局限性

  • 研究为1-2期、样本量22例、随访中位26个月,长期疗效与安全性仍需延长随访验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Donor availability and transplantation-related risks limit the broad use of allogeneic hematopoietic-cell transplantation in patients with transfusion-dependent β-thalassemia. After previously establishing that lentiviral transfer of a marked β-globin (βA-T87Q) gene could substitute for long-term red-cell transfusions in a patient with β-thalassemia, we wanted to evaluate the safety and efficacy of such gene therapy in patients with transfusion-dependent β-thalassemia. METHODS: In two phase 1-2 studies, we obtained mobilized autologous CD34+ cells from 22 patients (12 to 35 years of age) with transfusion-dependent β-thalassemia and transduced the cells ex vivo with LentiGlobin BB305 vector, which encodes adult hemoglobin (HbA) with a T87Q amino acid substitution (HbAT87Q). The cells were then reinfused after the patients had undergone myeloablative busulfan conditioning. We subsequently monitored adverse events, vector integration, and levels of replication-competent lentivirus. Efficacy assessments included levels of total hemoglobin and HbAT87Q, transfusion requirements, and average vector copy number. RESULTS: At a median of 26 months (range, 15 to 42) after infusion of the gene-modified cells, all but 1 of the 13 patients who had a non-β0/β0 genotype had stopped receiving red-cell transfusions; the levels of HbAT87Q ranged from 3.4 to 10.0 g per deciliter, and the levels of total hemoglobin ranged from 8.2 to 13.7 g per deciliter. Correction of biologic markers of dyserythropoiesis was achieved in evaluated patients with hemoglobin levels near normal ranges. In 9 patients with a β0/β0 genotype or two copies of the IVS1-110 mutation, the median annualized transfusion volume was decreased by 73%, and red-cell transfusions were discontinued in 3 patients. Treatment-related adverse events were typical of those associated with autologous stem-cell transplantation. No clonal dominance related to vector integration was observed. CONCLUSIONS: Gene therapy with autologous CD34+ cells transduced with the BB305 vector reduced or eliminated the need for long-term red-cell transfusions in 22 patients with severe β-thalassemia without serious adverse events related to the drug product. (Funded by Bluebird Bio and others; HGB-204 and HGB-205 ClinicalTrials.gov numbers, NCT01745120 and NCT02151526 .).

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Thompson AA, Walters MC, Kwiatkowski J, et al. Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia. N Engl J Med. 2018. PMID: 29669226. doi:10.1056/NEJMoa1705342

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。